Arcadia Biosciences Reports 11% Revenue Growth in Q2 2025, Zola Coconut Water Sales Surge 24%, Net Loss Widens by 520%

Reuters08-15
Arcadia Biosciences Reports 11% Revenue Growth in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025, Zola Coconut Water Sales Surge 24%, Net Loss Widens by 520%

Arcadia Biosciences Inc. (Nasdaq: RKDA) has announced its financial and business results for the second quarter and first half of 2025. The company's revenues increased by $149,000, or 11%, during the second quarter of 2025 compared to the same period in 2024, driven entirely by Zola coconut water sales. Zola revenues grew by $280,000, or 24%, during the same period, primarily due to higher sales volume. For the first half of 2025, revenues increased by $362,000, or 16%, compared to the first half of 2024, with Zola revenues rising by $846,000, or 47%, driven by increased distribution and higher sales volume. Operating expenses for the second quarter of 2025 increased by $1.956 million, representing a 30% rise compared to the same period in 2024. The net loss attributable to common stockholders for the second quarter was $4.458 million, compared to a net income of $1.061 million in the second quarter of 2024, marking a significant decrease of $5.519 million. Arcadia Biosciences also reported receiving 2.7 million shares of stock in ABVE and eliminating $1 million in liabilities. The company did not implement any price increases during 2024 or the first half of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512920-en) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment